Glaukos Keeps Its Eye on the Prize at J.P. Morgan

Glaukos is probably at the top of its game when it comes down to maintaining a presence in the micro-invasive glaucoma surgery (MIGS) market. The San Clemente, CA-based company reaffirmed its laser-like focus on the market during a presentation at the 37th annual J.P. Morgan Healthcare Conference earlier on Wednesday. Glaukos’ CEO Thomas Burns began his presentation speaking on the strengths of the firm and its goals going forward. “Our mission is aspirational,” Burns said. “As a company we are seeking to transform glaucoma therapy, and in doing so we want to transform ourselves into a hybrid surgical/pharmaceutical/medical device company." Are you ready for MD&M West? Join us from Feb. 5 - Feb. 7 for medtech's premiere event in Anaheim, CA.   That transformation kicked into high gear in 2018, as the company had approvals, product launches, and key developments in trials.  “As we look at our milestones we think we had a very high-performance year,” he said. “We were able to get a favorable review from FDA and have PMA approval for our iStent Inject well ahead of both our and investor expectations.  And that product is off to a superlative start.” iStent Inject is designed to optimize the natural physiological outflow of aqueous humor by creating two patent bypasses throug...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news